Literature DB >> 27133059

Effect of MicroRNA-218 on the viability, apoptosis and invasion of renal cell carcinoma cells under hypoxia by targeted downregulation of CXCR7 expression.

Shouhua Zhang1, Zhengdong Hong2, Qiang Li3, Jun Lei4, Hui Huang4, Queling Liu5.   

Abstract

OBJECTIVE: To investigate the effect of microRNA-218 on the viability, apoptosis and invasion of renal cell carcinoma cells under hypoxia by targeted regulation of expression of chemokine receptor 7 (CXCR7).
METHODS: The expression of miR-218 in renal cell carcinoma cell lines under normal and hypoxia conditions, as well in normal renal tubular epithelial cells (HK2) was measured using RT-PCR. MiR-218 mimic and NC were transfected into renal cell carcinoma cell line ACHN using Lipofectamine™ 2000. The expression of miR-218 was analyzed using RT-PCR. The viability, apoptosis, migration and invasion of the transfected cells were assayed using the MTT assay, flow cytometry and transwell assays. The expression of CXCR7 was assayed using RT-PCR and Western blot. Luciferase reporter was used to verify the downstream target of miR-218.
RESULTS: The expression of miR-218 was lower than in renal cell carcinoma cell lines ACHN, 769-p and Caki-1 that in HK-2. The expression of miR-218 in the renal carcinoma cell lines was lower under hypoxia than under normal oxygen conditions. The expression of miR-218 in ACHN cells under normal and hypoxic conditions was significantly increased after transfection with miR-218 mimic. Compared with NC transfected cells under normal oxygen condition, the mimic-transfected cells had reduced viability, migration ability and invasion ability, and increased apoptosis, and mimic transfected-cells under hypoxia had significantly reduced viability, migration ability and invasion ability, and increased apoptosis. Overexpression of miR-218 mimic resulted in significant reduction in the expression of CXCR7 at protein and mRNA levels under normal and hypoxic conditions. Luciferase reporter assay confirmed that CXCR7 is the target protein of miR-218.
CONCLUSION: Up-regulation of miR-218 expression in renal cell carcinoma under hypoxia can result in significant and targeted down-regulation of CXCR7 expression, which could reduce cell viability, migration and invasion ability and induce apoptosis in the cancer cells.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Chemokine receptor 7; Renal cell carcinoma; miR-218

Mesh:

Substances:

Year:  2016        PMID: 27133059     DOI: 10.1016/j.biopha.2016.03.011

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  5 in total

1.  MicroRNA-218 inhibits the proliferation, migration, and invasion and promotes apoptosis of gastric cancer cells by targeting LASP1.

Authors:  Le-Le Wang; Lei Wang; Xiao-Ying Wang; Di Shang; Sheng-Jie Yin; Li-Li Sun; Hong-Bo Ji
Journal:  Tumour Biol       Date:  2016-09-30

2.  Plasmatic miR-210, miR-221 and miR-1233 profile: potential liquid biopsies candidates for renal cell carcinoma.

Authors:  Francisca Dias; Ana Luísa Teixeira; Marta Ferreira; Bárbara Adem; Nuno Bastos; Joana Vieira; Mara Fernandes; Maria Inês Sequeira; Joaquina Maurício; Francisco Lobo; António Morais; Jorge Oliveira; Klaas Kok; Rui Medeiros
Journal:  Oncotarget       Date:  2017-10-11

3.  Andrographolide impedes cancer stemness and enhances radio-sensitivity in oral carcinomas via miR-218 activation.

Authors:  Po-Yu Yang; Pei-Ling Hsieh; Tong Hong Wang; Cheng-Chia Yu; Ming-Yi Lu; Yi-Wen Liao; Tzu-Hsin Lee; Chih-Yu Peng
Journal:  Oncotarget       Date:  2017-01-17

4.  Expression and prognostic value of CXCL12/CXCR4/CXCR7 axis in clear cell renal cell carcinoma.

Authors:  Milena Potić Floranović; Ana Ristić Petrović; Filip Veličković; Ljubinka Janković Veličković
Journal:  Clin Exp Nephrol       Date:  2021-06-09       Impact factor: 2.801

Review 5.  Advances in CXCR7 Modulators.

Authors:  Nicole Lounsbury
Journal:  Pharmaceuticals (Basel)       Date:  2020-02-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.